Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

Placebo-controlled trial … - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se

Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.

Artikel i vetenskaplig tidskrift
Författare Mikael Landén
Hans Nissbrandt
Christer Allgulander
Karin Sörvik
Christina Ysander
Elias Eriksson
Publicerad i Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Volym 32
Nummer/häfte 1
Sidor 153-61
ISSN 0893-133X
Publiceringsår 2007
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi
Sidor 153-61
Språk en
Länkar dx.doi.org/10.1038/sj.npp.1301216
Ämnesord Adult, Disability Evaluation, Double-Blind Method, Drug Administration Schedule, Female, Humans, Pain Measurement, methods, Paroxetine, therapeutic use, Placebos, Premenstrual Syndrome, drug therapy, psychology, Serotonin Uptake Inhibitors, therapeutic use, Treatment Outcome
Ämneskategorier Fysiologi


Serotonin reuptake inhibitors (SRIs) do not have to be administered continuously to be effective for premenstrual dysphoric disorder (PMDD), but can be given during luteal phases only. This is of practical importance, but also of theoretical interest since it suggests that the onset of action of SRIs is shorter in PMDD than in, for example depression. In this study, both continuous and intermittent SRI administration was compared with placebo, with the special purpose of analyzing if different PMDD symptoms respond differently depending on the treatment regimen. To this end, women meeting slightly modified DSM-IV criteria for PMDD (mean+/-SD age, 37+/-6.3 years) were treated for three menstrual cycles with paroxetine continuously, paroxetine during the luteal phase only, or placebo, the population completing at least one treatment cycle comprising 55-56 subjects per group. Continuous treatment with paroxetine reduced premenstrual symptoms effectively with a response rate of 85%. The effect size was highest for irritability (1.4) and lowest for lack of energy (0.5). Intermittent treatment was as effective as continuous treatment in reducing irritability, affect lability, and mood swings, but had a somewhat weaker effect on depressed mood and somatic symptoms. The study indicates that the response rate when treating PMDD with SRIs is high, and that irritability is a key target symptom. Symptoms such as irritability, affect lability, and mood swings appear to be more inclined to respond rapidly to SRIs, enabling intermittent treatment, than are, for example, the somatic symptoms.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?